The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer.
 
Makoto Ueno
Honoraria - Abbott Japan; AstraZeneca; Boston Scientific; Kyowa Hakko Kirin; Lilly; Novartis; Taiho Pharmaceutical; Yakult Honsha
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Merck Serono (Inst); Taiho Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
 
Masato Ozaka
No Relationships to Disclose
 
Hiroshi Ishii
Honoraria - Ajinomoto; Bayer; Daiichi Sankyo; Hospira; Kyowa Hakko Kirin; Lilly; Mochida Pharmaceutical Co. Ltd.; Nobelpharma; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); Torii Pharmaceutical (Inst)
 
Tosiya Sato
Honoraria - Lilly Japan
 
Masafumi Ikeda
Honoraria - Abbott Japan; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Guerbet; Kowa; Lilly; Nippon Kayaku; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer Yakuhin (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Kowa (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Yakult Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
 
Kazuhiro Uesugi
Honoraria - Novelpharm; Taiho Pharmaceutical; Yakult Pharmaceutical
 
Naohiro Sata
No Relationships to Disclose
 
Kouichirou Miyashita
No Relationships to Disclose
 
Nobumasa Mizuno
Honoraria - Kyowa Hakko Kirin; Lilly; Novartis; OncoTherapy Science; Pfizer; Taiho Pharmaceutical; Yakult Honsha
Speakers' Bureau - Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Eisai (Inst); Merck Serono (Inst); NanoCarrier (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zeria Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; Novartis; Pfizer; Taiho Pharmaceutical; Yakult Honsha
 
Kunihiro Tsuji
No Relationships to Disclose
 
Takuji Okusaka
Honoraria - Astellas Pharma; Baxter; Bayer Yakuhin; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Lilly; Merck Serono; Nippon Kayaku; Nobelpharma; Novartis; Pfizer; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Dainippon Sumitomo Pharma; Lilly; NanoCarrier; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Taiho Pharmaceutical; Zeria Pharmaceutical
Research Funding - AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); GlaxoSmithKline K.K. (Inst); Kowa (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Nippon Boehringer Ingelheim (Inst); Nobelpharma (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Sceti Medical Labo (Inst); Shizuoka Industry (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst); Zeria Pharmaceutical (Inst)
 
Junji Furuse
Honoraria - Ajinomoto; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Fujifilm; J-Pharma; Kyowa Hakko Kirin; Lilly; Meiji Seika Kaisha; Merck Serono; Mitsubishi Tanabe Pharma; Mochida Pharmaceutical Co. Ltd.; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Sandoz; Sawai Pharmaceutical Co; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical; Zeria Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Kyowa Hakko Kirin; Lilly; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Yakult Pharmaceutical; Zeria Pharmaceutical
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Hisamitsu Pharmaceutical (Inst); J-Pharma (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Nippon Kayaku (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Torii Pharmaceutical (Inst); Yakult Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)